

| Número de catálogo | HF813026 |
|---|---|
| Descripción |
Research Grade Fontolizumab (HF813026) is a humanized monoclonal antibody detecting Interferon gamma in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights
|
| Reactividad de especies | Human |
| Aplicaciones | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Especie huésped | Human |
| Clonalidad | Monoclonal |
| Isotipo | IgG1-nd |
| Sistema de expresión | Mammalian cells |
| Especies | Human |
| Objetivo | Interferon gamma, IFN-gamma, Immune interferon, IFNG |
| Nivel de endotoxinas | < 10 EU/mg |
| Pureza | >95% as determined by SDS-PAGE. |
| Purificación | Protein A/G purified from cell culture supernatant. |
| Número de acceso | P01579 |
| Forma | Liquid |
| Buffer de almacenamiento | 0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote. |
| Estabilidad y almacenamiento | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Nombres alternativos | HuZAF, 326859-36-3 |
| Fondo | Interferon gamma (Interferon gamma,IFN-gamma,Immune interferon,IFNG) is a ~19 kDa protein. Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription. Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits. 1. El Bougrini, J. et al. (2006) Cellular and molecular biology (Noisy-le-Grand, France) 52, 9-15. PMID: 16914093 2. Hisamatsu, H. et al. (1996) The Journal of experimental medicine 183, 1807-16. PMID: 8666937 3. Greenlund, AC. et al. (1993) The Journal of biological chemistry 268, 18103-10. PMID: 8349687 4. Akiyama, K. et al. (1994) FEBS letters 343, 85-8. PMID: 8163024 5. Fabunmi, RP. et al. (2001) Journal of cell science 114, 29-36. PMID: 11112687 6. Lah, TT. et al. (1995) FEBS letters 363, 85-9. PMID: 7729559 |
| Nota | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |

SDS-PAGE for Research Grade Fontolizumab




Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.
Correo: [email protected]


+86-027-65523339
Edificio C, No. 666, Calle Shendunsi, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский